PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives

Area of Science:

• Oncology
• Immunotherapy
• Diagnostic Assays

Background:

• Five PD-1/PD-L1 inhibitors are approved for urothelial carcinoma (UC).
• FDA and EMA restrictions necessitate PD-L1 testing for first-line treatment in platinum-ineligible patients.
• Concerns exist regarding the comparability and interchangeability of PD-L1 immunohistochemical assays.

Purpose of the Study:

• To review the interchangeability of PD-L1 testing algorithms and assays in urothelial carcinoma.
• To assess the predictive reliability of PD-L1 testing in urothelial carcinoma.
• To explore potential new and upcoming biomarkers for UC treatment.

Main Methods:

• Literature review focusing on PD-L1 testing in urothelial carcinoma.
• Analysis of current FDA and EMA guidelines and restrictions.
• Evaluation of emerging issues related to antibodies, test platforms, and scoring algorithms.

Main Results:

• Significant concerns regarding the comparability and interchangeability of PD-L1 assays in urothelial carcinoma.
• Variability in immunohistochemical testing platforms and scoring algorithms impacts assay comparability.
• Need for standardized PD-L1 testing to ensure reliable predictive value.

Conclusions:

• Standardization of PD-L1 testing is essential for reliable patient stratification in urothelial carcinoma.
• Further research is needed to validate new biomarkers and improve existing PD-L1 assays.
• Interchangeability of current PD-L1 assays remains a challenge, impacting treatment decisions.